Antidiabetic and cardiovascular drug utilisation in patients diagnosed with type 2 diabetes mellitus over the age of 80 years: A populationbased cohort study

Age and Ageing

Volumn 44, Issue 4, 2015, Pages 566-573

  Hamada, Shota ^a   Gulliford, Martin C ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

80 and over; Aged; Cardiovascular diseases; Drug utilisation; Older people; Type 2 diabetes mellitus

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; INSULIN; METFORMIN; SULFONYLUREA; CARDIOVASCULAR AGENT; GLUCOSE BLOOD LEVEL;

AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK REDUCTION; UNITED KINGDOM; VERY ELDERLY; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; METABOLISM; MULTICENTER STUDY; RETROSPECTIVE STUDY;

AGED, 80 AND OVER; BLOOD GLUCOSE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG UTILIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES;

EID: 84937418610     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afv065     Document Type: Article

References (30)

1. Health and Social Care Information Centre. Prescribing for Diabetes. England 2005-06 to 2013-14. 2014. http://www.hscic.gov.uk/catalogue/PUB14681/pres-diab-eng-200506-201314-rep. pdf (20 May 2014, date last accessed).
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
3. Preis SR, Hwang SJ, Coady S et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009; 119: 1728-35.
4. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91.
5. National Institute for Health and Care Excellence. Type 2 Diabetes. 2014. http://www.nice.org.uk/guidance/cg66/resources/cg66-type-2-diabetes-full-guideline2 (20 May 2014, date last accessed).
6. Cracknell R. The Ageing Population. Key issues for the New Parliament 2010. http://www.parliament.uk/documents/commons/lib/research/key_issues/Full-doc.pdf (20 May 2014, date last accessed).
7. Health and Social Care Information Centre. National Diabetes Audit-2011-12. 2013. http://www.hscic.gov.uk/catalogue/PUB12421 (20 May 2014, date last accessed).
8. Cruz-Jentoft AJ, Carpena-Ruiz M, Montero-Errasquín B, Sánchez-Castellano C, Sánchez-García E. Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus. J Am Geriatr Soc 2013; 61: 734-8.
9. Moreno G, Mangione CM. Management of cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: 2002-2012 literature review. J Am Geriatr Soc 2013; 61: 2027-37.
10. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991; 34: 877-90.
11. ACCORD Study GroupBuse JB, Bigger JT et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99: 21i-33i.
12. Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM. Trends in the prescription of antidiabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiol Drug Saf 2009; 18: 973-6.
13. Leal I, Romio SA, Schuemie M, Oteri A, Sturkenboom M, Trifirò G. Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone. Br J Clin Pharmacol 2013; 75: 861-8.
14. Gulliford MC, Charlton J, Latinovic R. Trends in antihypertensive and lipid-lowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?. J Hum Hypertens 2005; 19: 111-7.
15. Petri A, de Lusignan S, Williams J, Chan T, Majeed A. Management of cardiovascular risk factors in people with diabetes in primary care: cross-sectional study. Public Health 2006; 120: 654-63.
16. Kirkman MS, Briscoe VJ, Clark N et al. Diabetes in older adults. Diabetes Care 2012; 35: 2650-64.
17. Independent Scientific Advisory Committee for MHRA database research (ISAC). Annual Report Jan 2013-Dec 2013. https://www.gov.uk/government/uploads/system/uploads/ attachment_data/file/388569/con448379.pdf (20 May 2014, date last accessed).
18. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69: 4-14.
19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
20. Holden SE, Gale EA, Jenkins-Jones S, Currie CJ. How many people inject insulin? UK estimates from 1991 to 2010. Diabetes Obes Metab 2014; 16: 553-9.
21. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
22. Li Y, Hu Y, Ley SH, Rajpathak S, Hu FB. Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. Diabetes Care 2014; 37: 3106-13.
23. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
24. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-701.
25. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet 2002; 360: 7-22.
27. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
28. Ikeda Y, Shimada K, Teramoto T et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014; 312: 2510-20.
29. Shah BR, Booth GL, Lipscombe LL, Feig DS, Bhattacharyya OKBierman AS. Near equality in quality for medication utilization among older adults with diabetes with universal medication insurance in Ontario, Canada. J Eval Clin Pract 2014; 20: 176-83.
30. Baviera M, Cortesi L, Tettamanti M et al. Changes in prescribing patterns and clinical outcomes in elderly diabetic patients in 2000 and 2010: analysis of a large Italian population-based study. Eur J Clin Pharmacol 2014; 70: 965-74.